OSI-027; a Dual TORC1/TORC2 Inhibitor, Induces Bim- and Puma-Mediated Apoptosis In Lymphoid Malignancy

被引：0
|
作者：
Hendrickson, Andrea E. Wahner [1 ]
Gupta, Mamta [2 ]
Yun, Seongseok [3 ]
Shing, Jennifer C. [3 ]
Schneider, Paula A.
Peterson, Kevin L.
Karp, Judith E. [4 ]
Barr, Sharon [5 ]
Witzig, Thomas E. [2 ]
Kaufmann, Scott H. [1 ]
机构：
[1] Mayo Clin, Div Hematol & Oncol, Rochester, MN USA
[2] Mayo Clin, Div Hematol, Rochester, MN USA
[3] Mayo Clin, Dept Mol Pharmacol & Expt Therapeut, Rochester, MN USA
[4] Sidney Kimmer Comprehens Canc Ctr John Hopkins, Div Hematol Malignancies, Baltimore, MD USA
[5] OSI Pharmaceut, Translat Res, Boulder, CO USA
来源：
BLOOD | 2010年 / 116卷 / 21期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：427 / 428
页数：2
相关论文
共 6 条
  • [1] First-in-human phase I study exploring three schedules of OSI-027, a novel small molecule TORC1/TORC2 inhibitor, in patients with advanced solid tumors and lymphoma
    Tan, D. S.
    Dumez, H.
    Olmos, D.
    Sandhu, S. K.
    Hoeben, A.
    Stephens, A. W.
    Poondru, S.
    Gedrich, R.
    Kaye, S. B.
    Schoffski, P.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [2] OSI-027, a dual mTORC1/mTORC2 inhibitor, induces autophagy in cancer cells
    O'Connor, Matthew
    Mohan, Amrita
    Brady, Suzanne
    Mantis, Christine
    Gokhale, Prafulla C.
    Miglarese, Mark R.
    Barr, Sharon M.
    CANCER RESEARCH, 2011, 71
  • [3] RES529, A DUAL TORC1/TORC2 INHIBITOR, POTENTIATES THE IN VITRO AND IN VIVO EFFICACY OF HORMONE MANIPULATIONS IN THE 22RV1 PROSTATE CANCER CELL MODEL
    Gravina, Giovanni Luca
    Marampon, Francesco
    Colapietro, Alessandro
    Scarsella, Luca
    Jitariuc, Ana
    Sanita, Patrizia
    Sherris, David
    Festuccia, Claudio
    ANTICANCER RESEARCH, 2015, 35 (06) : 3638 - 3639
  • [4] Torc1/Torc2 inhibitor, Palomid 529, enhances radiation response modulating CRM1-mediated survivin function and delaying DNA repair in prostate cancer models
    Gravina, Giovanni Luca
    Marampon, Francesco
    Sherris, David
    Vittorini, Francesca
    Di Cesare, Ernesto
    Tombolini, Vincenzo
    Lenzi, Andrea
    Jannini, Emmanuele A.
    Festuccia, Claudio
    PROSTATE, 2014, 74 (08): : 852 - 868
  • [5] The Brain Penetrating and Dual TORC1/TORC2 Inhibitor, RES529, Elicits Anti-Glioma Activity and Enhances the Therapeutic Effects of Anti-Angiogenetic Compounds in Preclinical Murine Models
    Gravina, Giovanni Luca
    Mancini, Andrea
    Colapietro, Alessandro
    Delle Monache, Simona
    Sferra, Roberta
    Pompili, Simona
    Vitale, Flora
    Martellucci, Stefano
    Marampon, Francesco
    Mattei, Vincenzo
    Biordi, Leda
    Sherris, David
    Festuccia, Claudio
    CANCERS, 2019, 11 (10)
  • [6] Result of an open-label phase 2 trial of dual TORC1/TORC2 inhibitor onatasertib (ATG-008) in HBV+ advanced hepatocellular carcinoma (HCC) subjects who have received at least one prior line of systemic therapy (TORCH)
    Qin, Shukui
    Lin, Xiaoyan
    Meng, Zhiqaing
    Ren, Zhenggang
    Bai, Yuxian
    Gu, Shanzhi
    Zheng, Li
    Li, Qiu
    Oh, Sun-Yong
    Guo, Yabing
    Kang, Yoong-Koo
    Kao, Wei-Yu
    Li, Wei
    Yoon, Jung-Hwan
    Zhang, Helong
    Chen, Pei-Jer
    Yang, Tsai-Sheng
    Heo, Jeong
    Zheng, Zhendong
    Xie, Hui
    Yu, Zhinuan
    CANCER RESEARCH, 2023, 83 (08)
1